PUBLISHER: The Business Research Company | PRODUCT CODE: 1574677
PUBLISHER: The Business Research Company | PRODUCT CODE: 1574677
Competent cells are bacterial cells that have been treated to become capable of taking up foreign deoxyribonucleic acid (DNA). These cells are crucial in molecular biology for cloning and transformation experiments, as they facilitate the introduction of genetic material into the cells. The main goal of using competent cells is to enable the uptake of foreign DNA during the transformation process.
The primary types of competent cells are chemically competent cells, electrocompetent cells, and ultracompetent cells. Chemically competent cells are prepared through chemical treatments that increase their membrane permeability, allowing DNA to enter more easily. These cells are utilized in various applications such as cloning, protein expression, and mutagenesis. They are employed by a range of end users including contract research organizations, pharmaceutical and biotechnology companies, and academic research institutions.
The competent cells market research report is one of a series of new reports from The Business Research Company that provides competent cells market statistics, including competent cells industry global market size, regional shares, competitors with a competent cells market share, detailed competent cells market segments, market trends and opportunities, and any further data you may need to thrive in the competent cells industry. This competent cells market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The competent cells market size has grown rapidly in recent years. It will grow from $2.34 billion in 2023 to $2.65 billion in 2024 at a compound annual growth rate (CAGR) of 13.3%. The growth during the historic period can be attributed to several factors, including a rising demand for genetic cloning, increased government funding for life sciences research, expansion of the biotechnology workforce, a growing focus on rare disease research, and a rise in the outsourcing of research activities to contract research organizations.
The competent cells market size is expected to see rapid growth in the next few years. It will grow to $4.39 billion in 2028 at a compound annual growth rate (CAGR) of 13.4%. The anticipated growth during the forecast period can be attributed to several factors, including the rising demand for personalized medicine, increased investment in biotechnology startups, growing need for recombinant protein production, a higher prevalence of chronic diseases, and a surge in demand for industrial biotechnology solutions. Key trends expected to influence this growth include advancements in technology, the integration of artificial intelligence, developments in quantum computing, the adoption of 5G technology, and innovations in wearable technology.
The expansion of the biopharmaceutical industry is anticipated to drive the growth of the competent cells market. This industry focuses on the development, production, and commercialization of drugs derived from biological sources, utilizing biotechnology and molecular biology to create advanced therapies and treatments. The biopharmaceutical sector is growing due to rapid advancements in biotechnology, increased demand for personalized medicine, and rising investments in research and development for innovative treatments. Competent cells are crucial in this field for genetic engineering, gene cloning, and protein expression, facilitating the production of recombinant proteins, therapeutic enzymes, and other biologics necessary for drug development. For example, the Department of Health and Social Care, a UK-based government department, reported in May 2024 that the core biopharmaceutical sector generated £46.7 billion ($59.32 billion) in revenue during 2021/22, representing 43% of the total life sciences industry. Additionally, AusBiotech, an Australia-based organization, projected that the biotechnology sector would reach USD 5.66 billion (AU$ 8.67 billion) in revenue by 2024, reflecting a 4.4% growth rate. Consequently, the expanding biopharmaceutical industry is fueling the growth of the competent cells market.
Key companies in the competent cells market are introducing innovative kits, such as replication competent lentivirus kits, to improve cell and gene therapies and enhance the efficiency of genetic transformation processes. Cell and gene therapies involve modifying or using cells or genes to treat or cure diseases. For instance, Bio-Rad Laboratories Inc., a US-based clinical diagnostics manufacturer, released the Vericheck ddPCR replication competent lentivirus kit and the Vericheck ddPCR replication competent AAV kit in February 2024. These kits utilize advanced droplet digital PCR (ddPCR) technology to detect and quantify replication-competent lentivirus (RCL) and adeno-associated virus (AAV) with high sensitivity and precision. This technology is vital for ensuring the safety and effectiveness of viral vectors used in therapeutic applications by detecting and eliminating potentially harmful replication-competent viruses.
In June 2021, Hillhouse Capital Management Ltd., a private equity firm based in Hong Kong, acquired a 2.99% stake in Genscript Biotech Corporation from GenScript Corporation for HKD 1.2 billion ($0.15 billion). This acquisition aims to enhance Hillhouse Capital Management's biotechnology portfolio by leveraging Genscript Biotech Corporation's expertise in molecular biology and genetic engineering, thus fostering growth and innovation in advanced biotech solutions and services. Genscript Biotech Corporation, a US-based life sciences company, offers a range of products and services, including competent cells for molecular biology research and applications.
Major companies operating in the competent cells market are Thermo Fisher Scientific Inc., Avantor Inc., Agilent Technologies Inc., Sigma-Aldrich, Bio-Rad Laboratories Inc., QIAGEN N.V., Promega Corporation, GenScript Biotech Corporation, Takara Bio Inc., New England Biolabs Inc., TransGen Biotech Co. Ltd., HiMedia Laboratories Pvt. Ltd., Zymo Research Corporation, Lucigen Corporation, Meridian Bioscience Inc., Codex DNA Inc., OriGene Technologies Inc., SERVA Electrophoresis GmbH, SMOBIO Technology Inc., Yeastern Biotech Co. Ltd., Scarab Genomics LLC, Enzynomics Co. Ltd., NZYTech Lda., Gold Biotechnology Inc., Abyntek Biopharma S.L
North America was the largest region in the competent cells market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the competent cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the competent cells market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The competent cells market consists of sales of specialized competent cells, transformation kits, ready-to-use competent cells kits, and competent strain-specific cells. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Competent Cells Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on competent cells market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for competent cells ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The competent cells market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
The impact of higher inflation in many countries and the resulting spike in interest rates.
The continued but declining impact of COVID-19 on supply chains and consumption patterns.